Literature DB >> 31612390

Role of Mutant TBP in Regulation of Myogenesis on Muscle Satellite Cells.

Dong-Ming Zhao1, Sui-Qiang Zhu2, Fu-Rong Wang2, Shan-Shan Huang3.   

Abstract

In polyglutamine (PolyQ) diseases, mutant proteins cause not only neurological problems but also peripheral tissue abnormalities. Among all systemic damages, skeletal muscle dystrophy is the severest. Previously by studying knock-in (KI) mouse models of spinal cerebellar ataxia 17 (SCA17), it was found that mutant TATA box binding protein (TBP) decreases its interaction with myogenic differentiation antigen, thus reducing the expression of skeletal muscle structural proteins and resulting in muscle degeneration. In this paper, the role of mutant TBP in myogenesis was investigated. Single myofibers were isolated from tibialis anterior muscles of wild type (WT) and SCA17KI mice. The 1TBP18 staining confirmed the expression of mutant TBP in muscle satellite cells in SCA17KI mice. In the BaCl2-induced TA muscle injury, H&E cross-section staining showed no significant change in myofibril size before and after BaCl2 treatment, and there was no significant difference in centralized nuclei between WT and SCA17KI mice, suggesting that mutant TBP had no significant effect on muscle regeneration. In the cultured primary myoblasts from WT and SCA17KI mice in vitro, representative BrdU immunostaining showed no significant difference in proliferation of muscle satellite cells. The primary myoblasts were then induced to differentiate and immunostained for eMyHC, and the staining showed there was no significant difference in differentiation of primary myoblasts between WT and SCA1KI mice. Our findings confirmed that mutant TBP had no significant effect on myogenesis.

Entities:  

Keywords:  TATA box binding protein; myoblast; myogenesis; spinocerebellar ataxia 17

Mesh:

Substances:

Year:  2019        PMID: 31612390     DOI: 10.1007/s11596-019-2099-y

Source DB:  PubMed          Journal:  Curr Med Sci        ISSN: 2523-899X


  23 in total

Review 1.  Skeletal muscle in motor neuron diseases: therapeutic target and delivery route for potential treatments.

Authors:  Luc Dupuis; Andoni Echaniz-Laguna
Journal:  Curr Drug Targets       Date:  2010-10       Impact factor: 3.465

Review 2.  TATA-binding protein in neurodegenerative disease.

Authors:  W M C van Roon-Mom; S J Reid; R L M Faull; R G Snell
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

3.  Large Polyglutamine Repeats Cause Muscle Degeneration in SCA17 Mice.

Authors:  Shanshan Huang; Su Yang; Jifeng Guo; Sen Yan; Marta A Gaertig; Shihua Li; Xiao-Jiang Li
Journal:  Cell Rep       Date:  2015-09-17       Impact factor: 9.423

Review 4.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors:  Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal:  Histol Histopathol       Date:  2008-02       Impact factor: 2.303

5.  Unusual early-onset Huntingtons disease.

Authors:  Antonio P Vargas; Francisco J Carod-Artal; Denise Bomfim; Carolina Vázquez-Cabrera; Carmela Dantas-Barbosa
Journal:  J Child Neurol       Date:  2003-06       Impact factor: 1.987

Review 6.  Polyglutamine androgen receptor-mediated neuromuscular disease.

Authors:  Elisa Giorgetti; Andrew P Lieberman
Journal:  Cell Mol Life Sci       Date:  2016-05-17       Impact factor: 9.261

Review 7.  Skeletal muscle pathology in Huntington's disease.

Authors:  Daniel Zielonka; Izabela Piotrowska; Jerzy T Marcinkowski; Michal Mielcarek
Journal:  Front Physiol       Date:  2014-10-06       Impact factor: 4.566

8.  MiR-17 and miR-19 cooperatively promote skeletal muscle cell differentiation.

Authors:  Delin Kong; Mei He; Lin Yang; Rongtao Zhou; Yun-Qin Yan; Yang Liang; Chun-Bo Teng
Journal:  Cell Mol Life Sci       Date:  2019-06-18       Impact factor: 9.261

9.  Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1.

Authors:  Janghoo Lim; Juan Crespo-Barreto; Paymaan Jafar-Nejad; Aaron B Bowman; Ronald Richman; David E Hill; Harry T Orr; Huda Y Zoghbi
Journal:  Nature       Date:  2008-03-12       Impact factor: 49.962

10.  Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy.

Authors:  T A Rando; H M Blau
Journal:  J Cell Biol       Date:  1994-06       Impact factor: 10.539

View more
  1 in total

1.  CTRP1 Attenuates UUO-induced Renal Fibrosis via AMPK/NOX4 Pathway in Mice.

Authors:  Wen Li; Fan Cheng; Yi-Yan Songyang; Song-Yi-Sha Yang; Jie Wei; Yuan Ruan
Journal:  Curr Med Sci       Date:  2020-03-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.